In vivo muscarinic cholinergic receptor imaging in human brain with [11C]scopolamine and positron emission tomography
about
Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a reviewKinetic modeling of N-[11C]methylpiperidin-4-yl propionate: alternatives for analysis of an irreversible positron emission tomography trace for measurement of acetylcholinesterase activity in human brainPreclinical testing of N-[(11)c]-methyl-piperidin-4-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate, a novel radioligand for detection of cerebral muscarinic receptors using PETAssessment of muscarinic receptor concentrations in aging and Alzheimer disease with [11C]NMPB and PET.Acetylcholinesterase inhibition increases in vivo N-(2-[18F]fluoroethyl)-4-piperidyl benzilate binding to muscarinic acetylcholine receptors.Evaluation of novel PET ligands (+)N-[11C]methyl-3-piperidyl benzilate ([11C](+)3-MPB) and its stereoisomer [11C](-)3-MPB for muscarinic cholinergic receptors in the conscious monkey brain: a PET study in comparison with.Scopolamine disrupts hippocampal activity during allocentric spatial memory in humans: an fMRI study using a virtual reality analogue of the Morris Water Maze.Drug development for neurodegenerative diseases: role of PET.Evaluation of PET ligands (+)N-[(11)C]ethyl-3-piperidyl benzilate and (+)N-[(11)C]propyl-3-piperidyl benzilate for muscarinic cholinergic receptors: a PET study with microdialysis in comparison with (+)N-[(11)C]methyl-3-piperidyl benzilate in the coMechanisms underlying rapid experience-dependent plasticity in the human visual cortex.Basal forebrain moderates the magnitude of task-dependent amygdala functional connectivityFrom neuroscience to application in neuropharmacology: A generation of progress in electrophysiology.Imaging the head: functional imaging.Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjectsCholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatmentsDyskinesias in Parkinson's disease: views from positron emission tomography studies.Development of (18)F-labeled radiotracers for neuroreceptor imaging with positron emission tomographyWhy does the agonist [(18)F]FP-TZTP bind preferentially to the M(2) muscarinic receptor?Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects.In vivo detection of neurotransmitter changes in Alzheimer's disease.Methodological and theoretical issues in neural network models of frontal cognitive functions.Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjectsAge differences in muscarinic cholinergic receptors assayed with (+)N-[(11)C]methyl-3-piperidyl benzilate in the brains of conscious monkeys.(R)-N-[11C]methyl-3-pyrrolidyl benzilate, a high-affinity reversible radioligand for PET studies of the muscarinic acetylcholine receptor.Quantification of delta-opioid receptors in human brain with N1'-([11C]methyl) naltrindole and positron emission tomography.PET quantification of muscarinic cholinergic receptors with [N-11C-methyl]-benztropine and application to studies of propofol-induced unconsciousness in healthy human volunteers.A potential cholinergic mechanism of procaine's limbic activation.Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease.Scopolamine disrupts place navigation in rats and humans: a translational validation of the Hidden Goal Task in the Morris water maze and a real maze for humans.Quantification of muscarinic cholinergic receptors with [11C]NMPB and positron emission tomography: method development and differentiation of tracer delivery from receptor binding.PET studies of the uptake of (S)- and (R)-[11C]nicotine in the human brain: difficulties in visualizing specific receptor binding in vivo.Effects of trihexyphenidyl and L-dopa on brain muscarinic cholinergic receptor binding measured by positron emission tomography.[11C]tropanyl benzilate-binding to muscarinic cholinergic receptors: methodology and kinetic modeling alternatives.Muscarinic cholinergic receptor measurements with [18F]FP-TZTP: control and competition studies.GABAA agonist reduces visual awareness: a masking-EEG experiment.Kinetic evaluation of positron-emitting muscarinic receptor ligands employing direct intracarotid injection.In vivo quantification of cerebral muscarinic receptors in normal human aging using positron emission tomography and [11C]tropanyl benzilate.In vivo studies of acetylcholinesterase activity using a labeled substrate, N-[11C]methylpiperdin-4-yl propionate ([11C]PMP).Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration.Differential cholinergic regulation in Alzheimer's patients compared to controls following chronic blockade with scopolamine: a SPECT study.
P2860
Q26822244-536E7A7B-9871-415F-B4FA-D80DC940E2ACQ28374855-47E93ECB-5559-459F-B7C7-BF1CE83F3C53Q28377156-A0239152-3045-4B58-AC06-14314F972286Q31911220-26923793-19DF-40E2-9C12-822B9E4FFE4AQ31930884-8ED5CEA7-D228-499D-B839-2F66945363BAQ31949201-E85E33DB-EB0E-4FD7-BCD4-27D1263347E8Q33686599-043C2A1D-1916-48F9-BE2E-4FC5B02E67DAQ33841672-C5F3ECDA-7A75-4BD2-BB65-FA6077EDF0EEQ33942589-E37F1532-E698-45D9-AB24-E6CE6C1C8AC3Q33952154-FA447A51-9890-4837-837E-CD6A58BF80CDQ35237437-7AB0EBCB-E3F1-4815-8187-36580F838079Q36492225-0ACAA31B-4968-49AC-ABA6-71A959B7BA24Q36718204-06ADBEDA-7CF2-48ED-8A46-B85DE311FB3DQ36728072-0C55A2F4-CBCB-43E4-AA66-88AB7F04F2B7Q37576675-08B71ADA-7DC0-4924-9E78-7F000EC42BDCQ38182651-98460A04-D905-4DA3-B3E0-E95FD909FB11Q38244707-443FF652-FBEA-412C-AA5F-C5FABDF8CBA2Q39738564-EF76D7AC-2A77-484D-8960-F1D9B46092D6Q39784796-06283E13-1331-4842-9447-B6DA19E16328Q40618632-50C2A53F-F8C9-4850-B9FD-A45A62A43950Q40730698-EB3FBE78-23E1-44B6-A205-BF373CE9F454Q41634921-3AEA376B-C7FA-4DAE-86D9-3C5DA9D382D7Q43648298-9E3EAA7E-A002-41E6-B64A-EDB13B453798Q44060474-97D33880-9089-483F-A569-631FF3EBE6E1Q44352755-74459271-34DE-4B83-B7D9-8B9B2DC7506EQ44656415-E4C24781-7AB6-4DB0-8531-997455EF2E92Q44784139-C2BF6CCF-A082-49FB-BC4C-48B645C54335Q46900351-7EC6D969-CC8B-473E-85ED-9B1ECCE34380Q47868656-6F7A3C83-5099-4D76-BFD4-5B60A6338CCDQ47976364-5EB0AE87-A204-4211-BE64-4B8FBA4B4BB6Q48118527-33BBB140-8215-46EF-A693-66CAEE0704D2Q48194175-3A6CB592-8223-405B-B366-9CF70A26D619Q48198612-09AFA26C-66D6-42B3-B2E2-C44E16BB97DCQ48373600-8917E787-F53A-4225-82EA-D19056B70C1DQ48700757-A5A86126-C5CA-4CF4-84D8-AD378AB4ADF7Q48882699-BE0A9BB2-433D-4E17-BDDE-D933339EE430Q49108576-8803C6CA-E045-4A29-A97F-E81BB8B329BAQ49133963-2D4B178F-CFCE-4B8B-B6CB-C43048D5CB1BQ51991624-6B1D6B7B-36DF-4F95-9778-58621D11C538Q52013778-C0F71062-DECC-4703-8374-9541ED0D369C
P2860
In vivo muscarinic cholinergic receptor imaging in human brain with [11C]scopolamine and positron emission tomography
description
1992 nî lūn-bûn
@nan
1992 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
In vivo muscarinic cholinergic ...... d positron emission tomography
@ast
In vivo muscarinic cholinergic ...... d positron emission tomography
@en
In vivo muscarinic cholinergic ...... d positron emission tomography
@nl
type
label
In vivo muscarinic cholinergic ...... d positron emission tomography
@ast
In vivo muscarinic cholinergic ...... d positron emission tomography
@en
In vivo muscarinic cholinergic ...... d positron emission tomography
@nl
prefLabel
In vivo muscarinic cholinergic ...... d positron emission tomography
@ast
In vivo muscarinic cholinergic ...... d positron emission tomography
@en
In vivo muscarinic cholinergic ...... d positron emission tomography
@nl
P2093
P2860
P356
P1476
In vivo muscarinic cholinergic ...... d positron emission tomography
@en
P2093
B W Agranoff
D M Wieland
G K Mulholland
R A Koeppe
R L Ehrenkaufer
P2860
P304
P356
10.1038/JCBFM.1992.18
P407
P577
1992-01-01T00:00:00Z